Log in

Relevant bibliographies by topics / Normal tissue complication probabil / Journal articles

Journal articles on the topic 'Normal tissue complication probabil'

To see the other types of publications on this topic, follow the link: Normal tissue complication probabil.

Author: Grafiati

Published: 10 December 2022

Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Normal tissue complication probabil.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Andreassen, C. N. "SP-0555 SNPS FOR PREDICTION OF NORMAL TISSUE COMPLICATION RISK –PROBABLY NOT THE QUICK FIX THAT WE ONCE IMAGINED." Radiotherapy and Oncology 103 (May 2012): S222. http://dx.doi.org/10.1016/s0167-8140(12)70894-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Gurluler, Ercüment, Nazim Gures, Ilknur Citil, Ozgur Kemik, Ibrahim Berber, Aziz Sumer, and Alihan Gurkan. "Desmoid Tumor in Puerperium Period: A Case Report." Clinical Medicine Insights: Case Reports 7 (January 2014): CCRep.S13593. http://dx.doi.org/10.4137/ccrep.s13593.

Full text

Abstract:

Desmoid tumors (DTs) are rare tumors classified as deep fibromatoses taking origin from fascial or musculoaponeurotic structures. With pregnancy and surgical scars considered in the etiology, most anterior abdominal wall DTs occur in women in their reproductive years, especially during a pregnancy or post-partum. Herein, we present development of DT in a female patient in the post-partum period following cesarean delivery, which manifested itself with a growing mass in anterior abdominal wall. In our case, possibility of hematoma most probably located beneath the fascia was considered initially as a complication of cesarean section based on ultrasonographic examination and location of the lesion, while upon lack of either spontaneous regression with eventual diminish in size or resolve of symptoms within six weeks, further investigation via MRI and tru-cut biopsy revealed the diagnosis of abdominal DT. Radical tumor extirpation with resection of an adequate margin of surrounding normal tissue was applied, and the post-operative period was uneventful.

APA, Harvard, Vancouver, ISO, and other styles

3

Liden, Brock A., and Melitta Simmons. "Histologic Evaluation of a 6-Month GraftJacket Matrix Biopsy Used for Achilles Tendon Augmentation." Journal of the American Podiatric Medical Association 99, no. 2 (March 1, 2009): 104–7. http://dx.doi.org/10.7547/0980104.

Full text

Abstract:

Background: Assessing implanted biological reinforcement graft success in soft-tissue repairs is typically limited to noninvasive measurements and functional outcome measures. However, there are times when a histologic snapshot of the graft incorporation may be possible owing to a nongraft-related postoperative complication, such as hardware failure. Methods: We histologically evaluated a 6-month biopsy sample from an Achilles tendon repair augmented with an acellular human dermal matrix (AHDM). A 57-year-old woman was treated for Haglund’s deformity of the Achilles tendon. The Achilles tendon was fixed to the calcaneus using a plate, and an AHDM was used to augment the primary repair of the tendon. At 6 months, the hardware was removed owing to prominence, and a biopsy of the AHDM was performed. The specimen was prepared and stained using hematoxylin and eosin, Verhoeff-van Gieson, Movat’s pentachrome, and toluidine blue stains. Results: Visually, the graft appeared normal and incorporated with the native tendon. No repeated tear was observed, and results of tests for infection were negative. Histologically, the graft was infiltrated predominantly with fibroblasts and demonstrated numerous blood vessels. Positive proteoglycan staining in the AHDM and at sites of vascularity indicated probable transformation to tendon-like tissue. Conclusions: These histologic findings suggest that the AHDM is highly biocompatible, supports revascularization and repopulation with noninflammatory host cells, and becomes incorporated by surrounding tendon tissue. (J Am Podiatr Med Assoc 99(2): 104–107, 2009)

APA, Harvard, Vancouver, ISO, and other styles

4

Cabac, Vasile, Veronica Polovei, and Ala Istratenco. "Empty nose syndrome." Romanian Journal of Rhinology 7, no. 27 (September 27, 2017): 135–41. http://dx.doi.org/10.1515/rjr-2017-0015.

Full text

Abstract:

Abstract Empty nose syndrome (ENS) is a clinical entity lacking consensual meaning, illustrating a rare nose surgery complication, particularly of nasal conchae surgery, which results in the destruction of the normal nasal tissue. In severe forms it may become debilitating; the inability in identification and appreciation of this syndrome turns detrimental to the patient. Physiopathology remains controversial, which probably implies disorders caused by excessive nasal permeability, affecting neurosensory receptors as well as the humidification functions and conditioning of inhaled air. Neuropsychological involvement is being suspected. Symptomatology is both variable and changeable, the most evident sign outlining paradoxical nasal obstruction. The diagnosis is based on a series of symptoms that need to be collected precisely, the objective examination that highlights the permeability of nasal fossae. The management is problematic; there are implemented a complete range of simple hygiene and humidification techniques of the nasal cavity and, for more severe cases, surgery is provided, regardless of technique, the surgery targeting partial filling of the nasal airways. Prevention is the most essential strategy along with basic conservative surgical techniques.

APA, Harvard, Vancouver, ISO, and other styles

5

Rollin, Jérôme, Claire Pouplard, and Yves Gruel. "Risk factors for heparin-induced thrombocytopenia: Focus on Fcγ receptors." Thrombosis and Haemostasis 116, no. 11 (September 2016): 799–805. http://dx.doi.org/10.1160/th16-02-0109.

Full text

Abstract:

SummaryFcγ receptors have critical roles in the pathophysiology of heparin-induced thrombocytopenia (HIT), a severe immune-mediated complication of heparin treatment. Activation of platelets, monocytes and neutrophils by platelet-activating anti-PF4/heparin IgG antibodies results in thrombocytopenia, hypercoagulability and thrombosis in susceptible patients, effects that depend on FcγRIIA. In addition, FcγRIIIA receptors probably contribute to clearance of platelets sensitised by HIT immune complexes. FcγRI has also been reported to be involved in monocyte activation by HIT IgG antibodies and synthesis of tissue factor. This review focuses on the role of these FcγRs in HIT pathophysiology, including the potential influence of several gene variations associated with variable risk of HIT and related thrombosis. In particular, the 276P and 326Q alleles of CD148, a protein tyrosine phosphatase that regulates FcγRIIA signalling, are associated with a lower risk of HIT, and platelets from healthy donors expressing these alleles are hyporesponsive to anti-PF4/H antibodies. It was also recently demonstrated that the risk of thrombosis is higher in HIT patients expressing the R isoform of the FcγRIIA H131R polymorphism, with HIT antibodies shown to activate RR platelets more efficiently, mainly explained by an inhibitory effect of normal IgG2, which bound to the FcγRIIA 131H isoform more efficiently. Environmental risk factors probably interact with these gene polymorphisms affecting FcγRs, thereby increasing thrombosis risk in HIT.

APA, Harvard, Vancouver, ISO, and other styles

6

Ghanaati, Shahram, Adorján Kovács, Mike Barbeck, Jonas Lorenz, Anna Teiler, Nader Sadeghi, Charles James Kirkpatrick, and Robert Sader. "Bilayered, non-cross-linked collagen matrix for regeneration of facial defects after skin cancer removal: a new perspective for biomaterial-based tissue reconstruction." Journal of Cell Communication and Signaling 10, no. 1 (December 9, 2015): 3–15. http://dx.doi.org/10.1007/s12079-015-0313-7.

Full text

Abstract:

Abstract Classically skin defects are covered by split thickness skin grafts or by means of local or regional skin flaps. In the presented case series for the first time a bilayered, non-crossed-linked collagen matrix has been used in an off-label fashion in order to reconstruct facial skin defects following different types of skin cancer resection. The material is of porcine origin and consists of a spongy and a compact layer. The ratio of the two layers is 1:3 in favour of the spongy layer. The aim of the study was to investigate the potential of this matrix for skin regeneration as an alternative to the standard techniques of skin grafts or flaps. Six patients between 39 and 83 years old were included in the study based on a therapeutic trial. The collagen matrix was used in seven defects involving the nose, eyelid, forehead- and posterior scalp regions, and ranging from 1,2 to 6 cm in diameter. Two different head and neck surgeons at two different institutions performed the operations. Each used a different technique in covering the wound following surgery, i.e. with and without a latex-based sheet under the pressure dressing. In three cases cylindrical biopsies were taken after 14 days. In all cases the biomaterial application was performed without any complication and no adverse effects were observed. Clinically, the collagen matrix contributed to a tension-free skin regeneration, independent of the wound dressing used. The newly regenerated skin showed strong similarity to the adjacent normal tissue both in quality and colour. Histological analysis indicated that the spongy layer replaced the defective connective tissue, by providing stepwise integration into the surrounding implantation bed, while the compact layer was infiltrated by mononuclear cells and contributed to its epithelialization by means of a „conductive“process from the surrounding epithelial cells. The clinical and histological data demonstrate that the collagen bilayered matrix used in this series contributes to a „Guided-Integrative-Regeneration-Process“, which still needs to be further understood. The biomimetic nature of this material seems to contribute to physiological matrix remodelling, which probably involves other matricellular proteins essential for soft tissue regeneration. A deeper understanding of the mechanism, involved in the tissue integration of this material and its contribution to soft tissue regeneration based on the direct and indirect effect of matricellular proteins could open new therapeutic avenues for biomaterial-based soft tissue regeneration as an alternative to traditional flap-based plastic surgery.

APA, Harvard, Vancouver, ISO, and other styles

7

Kukołowicz, Paweł. "Clinical aspects of normal tissue complication probability." Reports of Practical Oncology & Radiotherapy 9, no. 6 (2004): 261–67. http://dx.doi.org/10.1016/s1507-1367(04)71038-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Xu, Cheng-Jian, Arjen van der Schaaf, Aart A. van't Veld, Johannes A. Langendijk, and Cornelis Schilstra. "Statistical Validation of Normal Tissue Complication Probability Models." International Journal of Radiation Oncology*Biology*Physics 84, no. 1 (September 2012): e123-e129. http://dx.doi.org/10.1016/j.ijrobp.2012.02.022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Lyman, John T. "Normal tissue complication probabilities: Variable dose per fraction." International Journal of Radiation Oncology*Biology*Physics 22, no. 2 (January 1992): 247–50. http://dx.doi.org/10.1016/0360-3016(92)90040-o.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Alexander, M. A. R., W. A. Brooks, and S. W. Blake. "Normal tissue complication probability modelling of tissue fibrosis following breast radiotherapy." Physics in Medicine and Biology 52, no. 7 (March 7, 2007): 1831–43. http://dx.doi.org/10.1088/0031-9155/52/7/005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Palma, G., A. Buonanno, S. Monti, R. Pacelli, and L. Cella. "OC-0512: Space based normal tissue complication probability modeling." Radiotherapy and Oncology 127 (April 2018): S267—S268. http://dx.doi.org/10.1016/s0167-8140(18)30822-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Tai, A., L. Grossheim, B. Erickson, and A. X. Li. "Modeling of Normal Tissue Complication Probability in Liver Irradiation." International Journal of Radiation Oncology*Biology*Physics 69, no. 3 (November 2007): S602—S603. http://dx.doi.org/10.1016/j.ijrobp.2007.07.1908.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Bentzen, Søren M. "Modeling normal-tissue complication probabilities: Where are we now?" Radiotherapy and Oncology 37 (October 1995): S6. http://dx.doi.org/10.1016/0167-8140(96)80450-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Hornby, Colin J., Trevor Ackerly, Andrew See, and Moshi Geso. "Exploring the effect of marked normal structure volume on normal tissue complication probability." Medical Dosimetry 28, no. 4 (December 2003): 223–27. http://dx.doi.org/10.1016/j.meddos.2003.08.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Kierkels, R. "SP-0390: Normal tissue complication modelling for improved radiotherapy planning." Radiotherapy and Oncology 152 (November 2020): S208—S209. http://dx.doi.org/10.1016/s0167-8140(21)00414-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Palma, Giuseppe, Serena Monti, Manuel Conson, Roberto Pacelli, and Laura Cella. "Normal tissue complication probability (NTCP) models for modern radiation therapy." Seminars in Oncology 46, no. 3 (June 2019): 210–18. http://dx.doi.org/10.1053/j.seminoncol.2019.07.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Bonta, Dacian V., Ernesto Fontenla, Yong Lu, and George T. Y. Chen. "A variable critical-volume model for normal tissue complication probability." Medical Physics 28, no. 7 (July 2001): 1338–43. http://dx.doi.org/10.1118/1.1380432.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Marks, Lawrence B., and Leonard R. Prosnitz. "Estimation of normal tissue complication probabilities with three-dimensional technology." International Journal of Radiation Oncology*Biology*Physics 28, no. 3 (February 1994): 777–79. http://dx.doi.org/10.1016/0360-3016(94)90207-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Marks, Lawrence B., Ellen D. Yorke, Andrew Jackson, Randall K. Ten Haken, Louis S. Constine, Avraham Eisbruch, Søren M. Bentzen, Jiho Nam, and Joseph O. Deasy. "Use of Normal Tissue Complication Probability Models in the Clinic." International Journal of Radiation Oncology*Biology*Physics 76, no. 3 (March 2010): S10—S19. http://dx.doi.org/10.1016/j.ijrobp.2009.07.1754.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Costalonga, Elerson C., Camilla Fanelli, Margoth R. Garnica, and Irene L. Noronha. "Adipose-Derived Mesenchymal Stem Cells Modulate Fibrosis and Inflammation in the Peritoneal Fibrosis Model Developed in Uremic Rats." Stem Cells International 2020 (May 20, 2020): 1–11. http://dx.doi.org/10.1155/2020/3768718.

Full text

Abstract:

Peritoneal fibrosis (PF) represents a long-term complication of peritoneal dialysis (PD), affecting the peritoneal membrane (PM) function. Adipose tissue-derived mesenchymal stem cells (ASC) display immunomodulatory effects and may represent a strategy to block PF. The aim of this study was to analyze the effect of ASC in an experimental PF model developed in uremic rats. To mimic the clinical situation of patients on long-term PD, a combo model, characterized by the combination of PF and chronic kidney disease (CKD), was developed in Wistar rats. Rats were fed with a 0.75% adenine-containing diet, for 30 days, to induce CKD with uremia. PF was induced with intraperitoneal injections of chlorhexidine gluconate (CG) from day 15 to 30. 1×106 ASC were intravenously injected at days 15 and 21. Rats were divided into 5 groups: control, normal rats; CKD, rats receiving adenine diet; PF, rats receiving CG; CKD+PF, CKD rats with PF; CKD+PF+ASC, uremic rats with PF treated with ASC. PF was assessed by Masson trichrome staining. Inflammation- and fibrosis-associated factors were assessed by immunohistochemistry, multiplex analysis, and qPCR. When compared with the control and CKD groups, GC administration induced a striking increase in PM thickness and inflammation in the PF and CKD+PF groups. The development of PF was blocked by ASC treatment. Further, the upregulation of profibrotic factors (TGF-β, fibronectin, and collagen) and the increased myofibroblast expression observed in the CKD+PF group were significantly ameliorated by ASC. Beyond the antifibrotic effect, ASC showed an anti-inflammatory effect avoiding leucocyte infiltration and the overexpression of inflammatory cytokines (IL-1β, TNF-α, and IL-6) in the PM induced by GC. ASC were effective in preventing the development of PF in the experimental model of CKD+PF, probably due to their immunomodulatory properties. These results suggest that ASC may represent a potential strategy for treating long-term PD-associated fibrosis.

APA, Harvard, Vancouver, ISO, and other styles

21

Gholami, Somayeh, Francesco Longo, Sara Shahzadeh, Hassan Ali Nedaie, Ryan Sharp, and Ali S.Meigooni. "Normal lung tissue complication probability in MR-Linac and conventional radiotherapy." Reports of Practical Oncology & Radiotherapy 25, no. 6 (November 2020): 961–68. http://dx.doi.org/10.1016/j.rpor.2020.09.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Ebert, Martin A., Sarah Gulliford, Oscar Acosta, Renaud de Crevoisier, Todd McNutt, Wilma D. Heemsbergen, Marnix Witte, Giuseppe Palma, Tiziana Rancati, and Claudio Fiorino. "Spatial descriptions of radiotherapy dose: normal tissue complication models and statistical associations." Physics in Medicine & Biology 66, no. 12 (June 17, 2021): 12TR01. http://dx.doi.org/10.1088/1361-6560/ac0681.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Kukołowicz, Paweł Franciszek. "Normal tissue complication probabilities (NTCP) for modified reverse hockey stick technique (MRHS)." Reports of Practical Oncology & Radiotherapy 12, no. 1 (January 2007): 31–38. http://dx.doi.org/10.1016/s1507-1367(10)60038-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Pacelli, R. "SP-0650: Advances in clinical radiobiology: modelling of normal tissue complication probability." Radiotherapy and Oncology 127 (April 2018): S345. http://dx.doi.org/10.1016/s0167-8140(18)30960-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

van Luijk, P. "IMPROVING NORMAL TISSUE COMPLICATION PROBABILITY MODELS: THE NEED TO INCLUDE BIOLOGICAL MECHANISMS." Radiotherapy and Oncology 98 (March 2011): S5. http://dx.doi.org/10.1016/s0167-8140(11)71715-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Szlag, Marta, and Krzysztof Ślosarek. "Two-dimensional imaging of tumour control probabilities and normal tissue complication probabilities." Reports of Practical Oncology & Radiotherapy 15, no. 2 (March 2010): 31–39. http://dx.doi.org/10.1016/j.rpor.2010.02.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Christophides, Damianos, Ane L. Appelt, Arief Gusnanto, John Lilley, and David Sebag-Montefiore. "Method for Automatic Selection of Parameters in Normal Tissue Complication Probability Modeling." International Journal of Radiation Oncology*Biology*Physics 101, no. 3 (July 2018): 704–12. http://dx.doi.org/10.1016/j.ijrobp.2018.02.152.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Tai, An, Beth Erickson, and X. Allen Li. "Extrapolation of Normal Tissue Complication Probability for Different Fractionations in Liver Irradiation." International Journal of Radiation Oncology*Biology*Physics 74, no. 1 (May 2009): 283–89. http://dx.doi.org/10.1016/j.ijrobp.2008.11.029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

D’Andrea, Marco, Marcello Benassi, and Lidia Strigari. "Modeling Radiotherapy Induced Normal Tissue Complications: An Overview beyond Phenomenological Models." Computational and Mathematical Methods in Medicine 2016 (2016): 1–9. http://dx.doi.org/10.1155/2016/2796186.

Full text

Abstract:

An overview of radiotherapy (RT) induced normal tissue complication probability (NTCP) models is presented. NTCP models based on empirical and mechanistic approaches that describe a specific radiation induced late effect proposed over time for conventional RT are reviewed with particular emphasis on their basic assumptions and related mathematical translation and their weak and strong points.

APA, Harvard, Vancouver, ISO, and other styles

30

McGinn, C. J., R. K. Ten Haken, W. D. Ensminger, S. Walker, S. Wang, and T. S. Lawrence. "Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model." Journal of Clinical Oncology 16, no. 6 (June 1998): 2246–52. http://dx.doi.org/10.1200/jco.1998.16.6.2246.

Full text

Abstract:

PURPOSE To attempt to safely escalate the dose of radiation for patients with intrahepatic cancer, we designed a protocol in which each patient received the maximum possible dose while being subjected to a 10% risk of radiation-induced liver disease (RILD, or radiation hepatitis) based on a normal tissue complication probability (NTCP) model. We had two hypotheses: H1; with this approach, we could safely deliver higher doses of radiation than we would have prescribed based on our previous protocol, and H2; the model would predict the observed complication probability (10%). PATIENTS AND METHODS Patients with either primary hepatobiliary cancer or colorectal cancer metastatic to the liver and normal liver function were eligible. We used an NTCP model with parameters calculated from our previous patient data to prescribe a dose that subjected each patient to a 10% complication risk within the model. Treatment was delivered with concurrent hepatic arterial fluorodeoxyuridine (HA FUdR). Patients were evaluated for RILD 2 and 4 months after the completion of treatment. RESULTS Twenty-one patients completed treatment and were followed up for at least 3 months. The mean dose delivered by the current protocol was 56.6 +/- 2.31 Gy (range, 40.5 to 81 Gy). This dose was significantly greater than the dose that would have been prescribed by the previous protocol (46.0 +/- 1.65 Gy; range, 33 to 66 Gy; P < .01). These data are consistent with H1. One of 21 patients developed RILD. The complication rate of 4.8% (95% confidence interval, 0% to 23.8%) did not differ significantly from the predicted 8.8% NTCP (based on dose delivered) and excluded a 25% true incidence rate (P < .05). This finding supports H2. CONCLUSION Our results suggest that an NTCP model can be used prospectively to safely deliver far greater doses of radiation for patients with intrahepatic cancer than with previous approaches. Although the observed complication probability is within the confidence intervals of our model, it is possible that this model overestimates the risk of complication and that further dose escalation will be possible. Additional follow-up and accrual will be required to determine if these higher doses produce further improvements in response and survival.

APA, Harvard, Vancouver, ISO, and other styles

31

Onuh, E., A. S. Ajuji, N. Rabiu, M. S. Anas, and M. Jada. "Normal tissue tolerance dose for cervical radiotherapy to the NTCP model using a method of least square fit." Bayero Journal of Pure and Applied Sciences 12, no. 1 (April 15, 2020): 215–20. http://dx.doi.org/10.4314/bajopas.v12i1.34s.

Full text

Abstract:

The purpose of this study is to evaluate the impact of Normal Tissue Complication Probability (NTCP) models on radiation treatment plans. We estimated NTCP parameters for the organs at risk (OARs) for cervical cancer radiotherapy. We pooled individual patient data from fifty patients who were treated with External Beam Radiotherapy technique between March 2012 and November 2013 in a part of Northern Nigeria with the exclusion of patients who had other gynaecological malignancies. Three basic methods were followed during the radiotherapy planning of these patients which included the pre-planning stage, planning radiotherapy treatment stage and treatment delivery. Various tests were carried out on these patients which helped to confirm the diagnosis after which they were treated using the linear accelerator, computed tomography simulator and the treatment planning system. We calculated the normal tissue tolerance doses for partial volumes of the organs using the values of the above –said parameters for published data on normal tissue tolerance doses. This article shows a graphical representation of the computed NTCP for left femur, right femur and skin presented and a fairly good correspondence is found between the curves for head of femurs and skin. Keywords: Normal Tissue Tolerance Dose, Normal Tissue Complication Probability, Method of Least Square Fit, Cervical Radiotherapy

APA, Harvard, Vancouver, ISO, and other styles

32

Tsai, Chiao-Ling, and Jason Chia-Hsien Cheng. "Evolving development of multi-parametric normal tissue complication probability model for liver radiotherapy." Translational Cancer Research 8, S2 (March 2019): S120—S123. http://dx.doi.org/10.21037/tcr.2018.11.25.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Godói, M., and P. Nicolucci. "THEORETICAL ANALYSIS OF FLASH EFFECT ON TUMOUR CONTROL AND NORMAL TISSUE COMPLICATION PROBABILITY." Physica Medica 94 (February 2022): S116—S117. http://dx.doi.org/10.1016/s1120-1797(22)01711-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Frometa-Castillo, Terman. "The Statistical Models Project (SMp) Normal Tissue Complication Probability (NTCP) Model and Parameters." American Journal of Applied Mathematics and Statistics 5, no. 4 (November 3, 2017): 115–18. http://dx.doi.org/10.12691/ajams-5-4-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Vågane, Randi, and Dag R. Olsen. "Analysis of normal tissue complication probability of the lung using a reliability model." Acta Oncologica 45, no. 5 (January 2006): 610–17. http://dx.doi.org/10.1080/02841860600658245.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Levin-Plotnik, Daphne, Andrzej Niemierko, and Solange Akselrod. "Effect of incomplete repair on normal tissue complication probability in the spinal cord." International Journal of Radiation Oncology*Biology*Physics 46, no. 3 (February 2000): 631–38. http://dx.doi.org/10.1016/s0360-3016(99)00372-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Cannev, P. A., R. Sanderson, C. Deehan, and T. Wheldon. "Variation in normal tissue complication probability with radiation technique in early breast cancer." European Journal of Cancer 34 (September 1998): S58—S59. http://dx.doi.org/10.1016/s0959-8049(98)80236-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Gordon, J., and J. Siebers. "258 oral PROBABILISTIC PLANNING REDUCES NORMAL TISSUE COMPLICATION PROBABILITIES IN PROSTATE IMRT PLANS." Radiotherapy and Oncology 99 (May 2011): S101—S102. http://dx.doi.org/10.1016/s0167-8140(11)70380-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Espensen, Charlotte A., Jens F. Kiilgaard, Ane L. Appelt, Lotte S. Fog, Joel Herault, Celia Maschi, Jean-Pierre Caujolle, and Juliette Thariat. "Dose-Response and Normal Tissue Complication Probabilities after Proton Therapy for Choroidal Melanoma." Ophthalmology 128, no. 1 (January 2021): 152–61. http://dx.doi.org/10.1016/j.ophtha.2020.06.030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

D'Avino, V., M. Conson, G. Palma, R. Liuzzi, M. Magliulo, R. Pacelli, and L. Cella. "Normal Tissue Complication Probability Models for Radiation-Induced Hypothyroidism in Hodgkin Lymphoma Survivors." International Journal of Radiation Oncology*Biology*Physics 96, no. 2 (October 2016): E638. http://dx.doi.org/10.1016/j.ijrobp.2016.06.2227.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Semenenko, V. A., and X. A. Li. "Prediction of Normal Tissue Complication Probability for Individual Patients Based on Published Data." International Journal of Radiation Oncology*Biology*Physics 75, no. 3 (November 2009): S474. http://dx.doi.org/10.1016/j.ijrobp.2009.07.1081.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Semenenko, Vladimir A., Sergey S. Tarima, Kiran Devisetty, Charles A. Pelizzari, and Stanley L. Liauw. "Validation of Normal Tissue Complication Probability Predictions in Individual Patient: Late Rectal Toxicity." International Journal of Radiation Oncology*Biology*Physics 85, no. 4 (March 2013): 1103–9. http://dx.doi.org/10.1016/j.ijrobp.2012.07.2375.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Chow, James C. L., Daniel Markel, and Runqing Jiang. "Technical Note: Calculation of normal tissue complication probability using Gaussian error function model." Medical Physics 37, no. 9 (August 26, 2010): 4924–29. http://dx.doi.org/10.1118/1.3483097.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

van der Schaaf, Arjien, Johannes Albertus Langendijk, Claudio Fiorino, and Tiziana Rancati. "Embracing Phenomenological Approaches to Normal Tissue Complication Probability Modeling: A Question of Method." International Journal of Radiation Oncology*Biology*Physics 91, no. 3 (March 2015): 468–71. http://dx.doi.org/10.1016/j.ijrobp.2014.10.017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Muren, L. P., A. Gustafsson, and O. Dahl. "Can dose response models predict reliable normal tissue complication probabilities in radiotherapy of urinary bladder cancer? A study of the impact of varying normal tissue complication probability models and parameters." International Journal of Radiation Oncology*Biology*Physics 48, no. 3 (January 2000): 355–56. http://dx.doi.org/10.1016/s0360-3016(00)80517-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Da Conceição, Maria Eduarda Bastos Andrade Moutinho, Danielli Martinelli Martins, Paulo Henrique Leal Bertolo, Daniella Kaísa de Oliveira Bezerra, Carmina Daniela Costa Ferreira da Silva, Lucien Roberta Valente Miranda De Aguirra, Rosemeri De Oliveira Vasconcelos, and Washington Luiz Assunção Pereira. "Squamous Cell Carcinoma in Third Eyelid of Cat." Acta Scientiae Veterinariae 44, no. 1 (January 16, 2016): 5. http://dx.doi.org/10.22456/1679-9216.82863.

Full text

Abstract:

Background: The third eyelid neoplasms are uncommon in cats. The squamous cell carcinoma are easily found in head and neck of same specie, although is unusual in eye region. The more commun localization is eyelid and eyeball, being 60 and 15%, respectively. It could bee diagnosed by citology, histopathology, imunohistochemistry and molecular biology. The surgery is more effective treatment, because the tumor can be totally removed and it must available surgical margin. The aim of this study was to report a case of squamous cell carcinoma in third eyelid of a cat and show how it was treated with radical surgery. Case: A 11-year-old spayed female domestic short-haired white and black colored cat was presented for evaluation at Maria Dias Teixeira Hospital of Amazonia Federal Rural University (UFRA), of an red ocular mass fast growth in the left eye for 2 months. Physical exam was within normal limits. The animal presented discomfort on the region, when it was manipulated. The mass was ulcerated and blood-tinged ocular discharge, had 3.3 x 2 cm, beginning on third eyelid and overlay all the eyeball. Blood was collated to make exams. Complete blood count and serum chemistry profiles were within normal ranges, but leukocytes were increased and it was treated with Amoxicillin (22 mg/kg). It was performed biopsy to histopathology and immunohistochemistry diagnose, and radiography and ultrasonography to found metastasis. Ocular tissues were fixed in 10% formalin and processed routinely for histological examination. Sections were stained with hematoxylin and eosin and diagnosed poorly differentiated Squamous cell carcinoma. Immunohistochemistry was performed using anti-cytokeratin 1:200, anti-vimentin 1:150 and anti-actin alpha smooth muscle 1:700 antibodies. The tumor cells were positive for cytokeratin and negative for vimentin. In tumor stroma was immunostaining of myofibroblasts by actina alpha smooth muscle. Because of malignment and infiltrative neoplasm, it was chosen to perform eye and eyelid enucleation. At post-operative evaluation no complication was found and in tem days, surgical wound was held. Seven months post-operative no neoplastic tissue had growth on local. Discussion: A retrospective study at Belem and some close cities, which took all neoplasms and classified, found only 1.5% of ocular neoplasms, and no one was in cats. Similarly occurred with another study, that 1.21% out of ocular masses, just 12.5% was diagnosed in cats, showing how uncommon is ocular neoplasm in cats. Including theses lesions, less of then are only in third eyelid. Ultraviolet radiation is the most related probably causes of squamous cell carcinoma. At Belem City ultravioleta radiation is very high, can bee 11 in some stations, in a scale of 0 to 14, the medial temperature is 27ºC. Another factor that could inﬂuence squamous cell carcionoma progress is skin color, animals’ wich skin is light have more probably to develop this neoplasm. On our case, close to eye, skin was dark, although the carcinoma was growth at third eyelid mucosa, a local that have no protection to ultraviolet radiation. Myofibroblasts observed in the tumor stroma are important in the invasion process of this tumor in humans. The treatment used in this case was radical surgery, with no other adjuvant, what is indicate for some authors. Another authors prefer exscind only third eyelid, but sometimes it is not possible, because this kind of neoplasm is very infiltrate. The localization and the nodular form of squamous cell carcinoma found in this study is uncommon, mainly in cats. Histopathological and immunohistochemical analysis were important for definitive diagnostic. The treatment by enucleation of eyeball and removing the eyelids was effective, without relapse in 7 months after surgery. Keywords: oncology, ophthalmology, ocular neoplasm, feline.

APA, Harvard, Vancouver, ISO, and other styles

47

Mehjabin, Monika, Mohammed Kamal, Md Abdus Sabur Talukder, Mizanur Rahman, Md Mozzamel Hoque, Farhad Uddin Ahmed, Md Shamsuddoha Khan, and Muhammad Tanvir Alam Akhanda. "Perforated Meckel’s Diverticulum with Pancreatic and Gastric Heterotropia and Acute Peritonitis - A Case Report." Journal of Shaheed Suhrawardy Medical College 12, no. 2 (January 3, 2022): 115–18. http://dx.doi.org/10.3329/jssmc.v12i2.56893.

Full text

Abstract:

Meckel’s diverticulum, the most common congenital anomaly of small bowel although usually silent, can cause complications like intestinal obstruction, bleeding, diverticulitis, perforation etc. We report a case, which presented with acute onset of severe pain in right iliac fossa which was clinically and sonographically diagnosed as acute appendicitis. Histopathological report of appendix was non specific findings. Four days after appendectomy patient again came with features of acute abdomen. X-ray abdomen showed free gas under diaphragm. Abdomen was explored with a midline incision, a perforated Meckel’sdiverticulum was found which was managed by wedge resection and repair of the ileum. Histopathological examination of specimen revealed diverticular wall with normal appearing intestinal mucosa and muscle coat which showed two heterotrophic tissues (pancreatic and gastric ) in the wall.These also showed features of perforation and acute peritonitis. This is probably the first case of Meckel’s diverticulitis with heterotropic pancreatic and gastric tissue in Bangladesh. J Shaheed Suhrawardy Med Coll 2020; 12(2): 115-118

APA, Harvard, Vancouver, ISO, and other styles

48

Hakman, Eryk, and Sasha Mikhael. "Clinical Report of Probable Catastrophic Antiphospholipid Syndrome in Pregnancy." Case Reports in Obstetrics and Gynecology 2018 (2018): 1–3. http://dx.doi.org/10.1155/2018/4176456.

Full text

Abstract:

Background. Catastrophic APS (CAPS) is a rare but life-threatening form of APS defined as multiorgan thrombosis affecting a minimum of three organs with confirmation by histopathology of small vessel occlusions in at least one organ or tissue. The development of CAPS in pregnancy poses many diagnostic challenges as a result of its broad range of clinical presentations and its overlap with other obstetric complications and microangiopathic diseases. Because of the high associated mortality rate, prompt recognition and treatment are paramount. Case. A twenty-five-year-old G3P0111 with a history of multiple thromboembolisms presented at 21 weeks and 3 days of gestation with complaints of right upper quadrant pain, visual disturbances, headache, and syncopal episodes. Laboratory evaluation demonstrated microangiopathic disease with hemolysis (confirmed on peripheral smear), elevated liver enzymes, and abnormal 24-hour urine protein with vital signs within the normal range. Presence of significantly elevated antiphospholipid antibodies was noted, facilitating the diagnosis of probable CAPS. Proper workup was achieved based on clinical suspicion, allowing immediate and appropriate management. Conclusion. CAPS is a life-threatening condition rarely seen in pregnancy making early recognition difficult. A low threshold to initiate urgent and aggressive treatment should be maintained to minimize the risk of adverse outcomes.

APA, Harvard, Vancouver, ISO, and other styles

49

Vinnikov, V. A., and T. V. Rubleva. "Predictors of radiation-induced complications in radiation oncology based on cell survival tests after ex vivo exposure: literature review." Український радіологічний та онкологічний журнал 29, no. 1 (March 29, 2021): 89–118. http://dx.doi.org/10.46879/ukroj.1.2021.89-118.

Full text

Abstract:

Background. Among cancer patients receiving radiotherapy about 5–15 % may have adverse reactions in normal tissues and organs that limit their treatment in a full, originally scheduled regimen. The development of biomarkers and assays for radiation oncology allowing the prediction of patients’ normal tissue toxicity requires a lot of resourses, threfore its current status amd potential directions for future research have to be periodically analyzed and re-evaluated. Purpose – this review summarizes the methodological approaches and developments in the area of functional laboratory assays based on ex vivo cell survival for the prediction of the individual clinical radiosensitivity. Materials and methods. Data for the analysis and systematization were obtained from the full-text articles published in peer review international scientific journals (in English) in 1990–2020, which were selected by the extensive search in PubMed information database and cross references on the topic “Functional cellular tests for intrinsic radiosensitivity to predict adverse radiation effects and radiotherapy complications”. Results. In theory, it might be expected that clonogenic cell survival after ex vivo irradiation can surve as the best individual predictor of radiation toxicity, as it is an integral indicator of cell damage and decline of their regenerative potential. Tendentially, fibroblasts, as a test system for such studies, did not show significant advantages over lymphocytes either in detecting inter-individual variations in the intrinsic cellular radiosensitivity or in predicting clinical radiation toxicity, even for that in skin. It was found that clonogenic cell survival assay, being very time consuming and technically demanding, also suffers from the lack of sensitivity and specificity, essential uncertainty and low reproducibility of the results, and thus is not suitable for the sceening for the abnormal intrinsic radiosensitivity. However, this type of assays is applicable for the radiobiological expertise post factum in individual cases with unexpected, extreme radiation lesions. Radiation-induced lymphocyte apoptosis assay seems to be more promising however still requires further fundamental research for better understanding of its background and more validation studies in order to assess the optimum patient groups, radiotherapy regimens and adverse effects for its confident use in clinical practice. Changes in the regulation of cell cycle check-points (radiationinduced delay) ex vivo can have either positive or inverted association, or no correlation with clinical radiation responses in tissues, thus so far cannot be included in the toolbox of applied radiobiological tests. Conclusions. To date, in the practice of clinical radiobiology, there are no fully validated and standardized functional tests based on the cell survival after ex vivo irradiation, which would allow a sufficiently accurate prediction of adverse radiation effects in normal tissues of radiotherapy patients. In general, ex vivo tests based on the evaluation of only one form of cell death in one cell type are not fully reliable as a “stand alone” assay, because different pathways of cell death probably play different roles and show different dose response within the overal reaction of the irradiated tissue or critical organ. Such tests should become a part of the multiparametric predictive platforms.

APA, Harvard, Vancouver, ISO, and other styles

50

Rahman, M. "Analysis of normal tissue complication probability-based radiobiological models: a systematic review of literatures." Breast 56 (April 2021): S29—S30. http://dx.doi.org/10.1016/s0960-9776(21)00116-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!